CClinicalTrials.gg
Active, not recruitingNCT04725643CALMUpdated Jan 23, 2024

Keep Contraceptive Arm Long Acting-iMplant (CALM) and Carry On

An observational study in Contraception, Contraceptive Usage and Family Planning, sponsored by University of California, San Diego. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by University of California, San Diego · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
55
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

The investigators will conduct an observational study comparing the number of bleeding days before and after contraceptive implant (Nexplanon) replacement.

Read the detailed description

There is very limited information regarding number of bleeding days after replacement of the contraceptive implants (Nexplanon). More detailed information on this topic will help clinicians counsel patients and help women decide if they would like to pursue contraceptive implant replacement.

The investigators will conduct a prospective cohort study of (N=114) among women replacing their contraceptive implant. The primary outcome of the study is the difference in number of bleeding days between the 4-week periods before and after implant replacement. Secondary outcomes include satisfaction with bleeding. Additionally, a secondary outcome will be the number of bleeding days in month 2 and month 3 after replacement of the contraceptive implant. The outcomes will be measured in bleeding diaries and satisfaction surveys.

Through a text messaging application, the investigators will send the participants hyperlinks to the diaries/surveys at the stated time points. Participants will report if they had bleeding and the amount based on the Pictorial Blood Assessment Chart (Higham). Participants will complete weekly surveys regarding their satisfaction with their bleeding utilizing a Likert scale. The investigators will also ask participants to complete a survey regarding their satisfaction with their bleeding at end of month 2 and at the end of month 3 after replacement of their contraceptive implant.

02

Conditions studied

  • Contraception
  • Contraceptive Usage
  • Family Planning

Keywords

  • Nexplanon, Contraceptive implant
03

In context

Lead sponsor

University of California, San Diego is the lead sponsor of 958 studies on the registry; 191 are open to participants now.

Of its 110 completed or terminated interventional studies of FDA-regulated products, 70 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients scheduled at UC San Diego for a contraceptive implant after approximately 3 years (32-40 months) of use.

Inclusion criteria

  • Reproductive aged women 18-50 years old
  • With a contraceptive implant (for patient participants)
  • Able to consent in English
  • Palpable contraceptive implant

Exclusion criteria

Exclusion Criteria:

  • Non-palpable contraceptive implant
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
55 participants (actual)
Patient registry
No

Groups and cohorts

  • Implant Group

    Adults who are choosing to get a replacement Nexplanon and agree to track and report their bleeding patterns for one month before replacement and 3 months after.

    Device: Track bleeding patterns before and after implant

Interventions

  • DeviceTrack bleeding patterns before and after implant

    Participants will report if they had bleeding and the amount based on the Pictorial Blood Assessment Chart. Participants will also complete weekly surveys regarding their satisfaction with their bleeding. We will also ask participants to complete a survey regarding their satisfaction with their bleeding at end of month 2 and at the end of month 3 after replacement of their contraceptive implant.

06

What researchers measure

Primary outcomes

  1. Number of bleeding days during 4 weeks before replacement

    Number of days participants experienced bleeding during the 4 weeks before implant replacement.

    Time frame: 4 weeks (28 days) before day of implant replacement.

  2. Number of bleeding days 4 weeks after replacement

    Number of days participants experienced bleeding during the 4 weeks after implant replacement.

    Time frame: 4 weeks (28 days) after day of implant replacement

Secondary outcomes

  1. Satisfaction with bleeding before replacement

    Using a 1-5 Likert scale with 1=Not Satisfied and 5=Very Satisfied, participants will report satisfaction with their bleeding before implant replacement.

    Time frame: 4 weeks (28 days) before day of implant replacement

  2. Satisfaction with bleeding after replacement

    Using a 1-5 Likert scale with 1=Not Satisfied and 5=Very Satisfied, participants will report satisfaction with their bleeding after replacement

    Time frame: 4 weeks (28 days) after day of implant replacement

  3. Number of bleeding days during the second month after implant replacement

    Number of days participants experienced bleeding during the second month after implant replacement

    Time frame: Second month (defined as 29-56 days) after implant replacement

  4. Number of bleeding days during the third month post replacement

    Number of days participants experienced bleeding during the third month after implant replacement

    Time frame: Third month (defined as 57-84 days) after implant replacement

07

Study locations

1 site
  • University of California, San Diego
    La Jolla, California 92093, United States
08

References and documents

Publications

  • Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990 Aug;97(8):734-9. doi: 10.1111/j.1471-0528.1990.tb16249.x. PubMed 2400752 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04725643
Lead sponsor
University of California, San Diego
Collaborators
Merck Sharp & Dohme LLC
Responsible party
Sheila Mody (Associate Professor, University of California, San Diego) — Principal investigator
First posted
Jan 27, 2021
Start date
Feb 17, 2022
Primary completion
Jan 11, 2024
Completion
Dec 31, 2024 (estimated)
Last update
Jan 23, 2024

Study contacts

Sheila Mody, MD, MPH
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion